Clinical Trial Update: QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating QL1706 in combination with chemotherapy, with or without bevacizumab, as first-line therapy for relapsed/metastatic triple-negativ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• QL1706

Snippet

Sponsor: Fudan University | Conditions: TNBC, Triple Negative Breast Cancer | Phase 2 | Status: RECRUITING